Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ranolazine and dronedarone on atrial fibrillation burden in paroxysmal atrial fibrillation
2011-001134-42Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ranolazine and dronedarone in Atrial fibrillation (AFib) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Change from baseline in atrial fibrillation burden (percent change) and Change from baseline in atrial fibrillation burden (absolute change). Started Dec 2011; status: completed.
02
Drugs
ranolazinedronedarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2011-001134-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001134-42.